Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.73 USD
Change Today -0.0099 / -0.57%
Volume 10.7K
As of 5:20 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

myos corp (MYOS) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/17/14 - $16.75
52 Week Low
08/26/15 - $1.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYOS CORP (MYOS)

Related News

No related news articles were found.

myos corp (MYOS) Related Businessweek News

No Related Businessweek News Found

myos corp (MYOS) Details

MYOS Corporation, a bionutrition and biotherapeutics company, engages in the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. The company primarily focuses on developing the products that improve muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include MYO-T12, a clinical myostatin inhibitor, which is distributed in the United States under the MYO-X brand name to specialty retail and other outlets; and Cenegenics Muscle Formula, a private-label product distributed within the age management network. The company was formerly known as Atlas Therapeutics Corporation and changed its name to MYOS Corporation in May 2012. MYOS Corporation was founded in 2007 and is based in Cedar Knolls, New Jersey.

9 Employees
Last Reported Date: 03/27/15
Founded in 2007

myos corp (MYOS) Top Compensated Officers

Principal Executive Officer, President and Ch...
Total Annual Compensation: $265.8K
Chief Financial Officer
Total Annual Compensation: $145.0K
Chief Medical Officer and Member of the Scien...
Total Annual Compensation: $288.3K
Compensation as of Fiscal Year 2014.

myos corp (MYOS) Key Developments

MYOS Corporation, Q1 2015 Earnings Call, May 14, 2015

MYOS Corporation, Q1 2015 Earnings Call, May 14, 2015

MYOS Corporation, Q4 2014 Earnings Call, Mar 30, 2015

MYOS Corporation, Q4 2014 Earnings Call, Mar 30, 2015

MYOS Corporation's Preclinical Study of Fortetropin's Mechanism of Action Demonstrate Regulatory Effects on Three Key Muscle Health Pathways

MYOS Corporation announced that its mechanism of action studies have identified three key molecular signaling pathways in which Fortetropin™ exhibits regulatory effects. In addition to reducing serum myostatin levels, MYOS recently completed a preclinical mechanism of action study that demonstrated Fortetropin's activity in mTOR and Ubiquitin, two other crucial signaling pathways in the growth and maintenance of healthy muscle. Myostatin is a naturally occurring regulatory protein which prevents muscle growth. Myostatin serum levels increase as people age which can lead to age-related muscle loss or sarcopenia. Fortetropin's ability to reduce serum myostatin levels has been clinically proven. Regulation of myostatin may be a key element in the treatment of sarcopenia. In addition to myostatin regulation, MYOS' preclinical data also showed that Fortetropin up-regulates the mTOR regulatory pathway. The mTOR pathway is responsible for production of a protein kinase related to cell growth and proliferation that increases skeletal muscle mass. Up-regulation of the mTOR pathway is important in preventing muscle atrophy. Fortetropin's ability to affect the mTOR pathway may have a significant impact in treating patients suffering from degenerative muscle diseases and suggests that Fortetropin-based products may help slow muscle loss secondary to immobility and denervation. Finally, the Company's recent animal model study demonstrated that Fortetropin acts to reduce the synthesis of proteins in the Ubiquitin pathway, a highly selective, tightly regulated system that serves to activate muscle breakdown. Over-production in the Ubiquitin pathway is responsible for muscle degradation. Fortetropin's ability to regulate production in the Ubiquitin pathway may have significant implications for repairing age-related muscle loss and for patients suffering from chronic diseases causing cachexia.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYOS:US $1.73 USD -0.0099

MYOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MYOS.
View Industry Companies

Industry Analysis


Industry Average

Valuation MYOS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.9x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYOS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at